Beyond its effects on insulin and glucagon, it exhibits a wide range of actions, including the promotion of insulin sensitivity in adipose tissue, stimulation of energy expenditure and lipolysis in the adipose tissue, reduction of hepatic steatosis and liver lipid content, deceleration of gastric emptying and gastrointestinal motility, and augmentation of satiety while reducing appetite and food intake through actions in the brain [1]. The gene discussed is INS; the disease is fatty liver disease.